Edvinsson L, McCulloch J, Sharkey J
Br J Pharmacol. 1985 Jun;85(2):403-10. doi: 10.1111/j.1476-5381.1985.tb08875.x.
The vasomotor responses of individual cerebral pial arterioles on the convexity of the cerebral cortex to subarachnoid perivascular micro-injections of dopamine and the putative dopamine receptor agonists, apomorphine, SKF 38393 and LY 141865, have been examined in 38 anaesthetized cats. The perivascular microapplication of dopamine (10(-9)-10(-3)M) effected dose-dependent reductions in pial arteriolar calibre, with the maximum reductions in calibre (22 +/- 2% from preinjection levels: mean +/- s.e.) being observed at 10(-3)M. The cerebrovascular constriction produced by dopamine (10(-5)M) could be significantly attenuated by the concomitant perivascular administration of phentolamine (10(-6)M) or methysergide (10(-6)M). The perivascular microapplication of apomorphine (10(-8)-10(-4)M) effected dose-dependent increases in arteriolar calibre, with the maximum increase (31 +/- 6%) being observed with apomorphine (10(-5)M). The perivascular administration of the putative dopamine D1-receptor agonist, SKF 38393 (10(-9)-10(-4)M) increased arteriolar calibre, with the maximum response (24 +/- 3%) being observed with injection of 10(-7)M. The putative dopamine D2-receptor agonist, LY 141865, also increased cerebral arteriolar calibre, but only at high concentrations (maximum calibre increase 25 +/- 6.1 with 10(-4)M). The cerebrovascular dilatations elicited by apomorphine and by SKF 38393 were markedly attenuated by the concomitant perivascular microapplication of the putative dopamine D1-receptor antagonist, SCH 23390 (10(-8)M). The perivascular administration of SCH 23390 (10(-9)-10(-5)M) per se did not alter arteriolar calibre nor the arteriolar dilatation provoked by microinjections of acidic cerebrospinal fluid. These results point to the presence on cat cerebral arterioles of dopamine receptors (probably of D1 subtype) mediating dilation.
在38只麻醉猫中,研究了大脑皮质凸面单个软脑膜小动脉对蛛网膜下腔血管周围微量注射多巴胺以及假定的多巴胺受体激动剂阿扑吗啡、SKF 38393和LY 141865的血管舒缩反应。血管周围微量应用多巴胺(10⁻⁹ - 10⁻³M)可使软脑膜小动脉管径呈剂量依赖性减小,在10⁻³M时观察到最大管径减小(较注射前水平减小22±2%:均值±标准误)。多巴胺(10⁻⁵M)引起的脑血管收缩可被同时血管周围给予酚妥拉明(10⁻⁶M)或麦角新碱(10⁻⁶M)显著减弱。血管周围微量应用阿扑吗啡(10⁻⁸ - 10⁻⁴M)可使小动脉管径呈剂量依赖性增加,阿扑吗啡(10⁻⁵M)时观察到最大增加(31±6%)。假定的多巴胺D1受体激动剂SKF 38393(10⁻⁹ - 10⁻⁴M)血管周围给药可增加小动脉管径,注射10⁻⁷M时观察到最大反应(24±3%)。假定的多巴胺D2受体激动剂LY 141865也可增加大脑小动脉管径,但仅在高浓度时(10⁻⁴M时最大管径增加25±6.1)。阿扑吗啡和SKF 38393引起的脑血管扩张可被同时血管周围微量应用假定的多巴胺D1受体拮抗剂SCH 23390(10⁻⁸M)显著减弱。血管周围给予SCH 23390(10⁻⁹ - 10⁻⁵M)本身不会改变小动脉管径,也不会改变微量注射酸性脑脊液引起的小动脉扩张。这些结果表明猫大脑小动脉上存在介导扩张的多巴胺受体(可能是D1亚型)。